The abstract is read at the publisher; the summary is JClub's.
Medicines newly added to the WHO Model List of Essential Medicines (2002–2023) show lower uptake in lower-GDP countries, and complex genomic diagnostics are linked to 65% lower standard-unit uptake overall.
- Why it matters: Access to precision oncology medicines may lag behind essential-list inclusion, especially where testing capacity and affordability differ across economic settings.
- What they did: This retrospective observational analysis used IQVIA MIDAS data (Jan 1, 2002–Dec 31, 2023) for 41 EML cancer medicines across 71 countries, grouped into lower-, middle-, and high-GDP strata, and tested associations by medicine diagnostic requirement.
- The result: At EML inclusion, uptake was reported in 20/25 lower-GDP countries for immunohistochemistry, 11/25 for complex genomics, and 16/25 for neither; across GDP groups, complex-genomics medicines had regression coefficient -0·453 (95% CI -0·562 to -0·344; p<0·0001) versus none.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.